The adjusted rate of opioid use increased nearly 4-fold (adjusted odds ratio, 4.18; 95% CI, 1.76-9.96), from 4.7% among new immigrants to 14.8% among those who had been in this country for 15 years or more.
From 2015 to 2017, number of opioid-involved overdose deaths increased for nearly all racial/ethnic groups.
The Canadian Research Initiative in Substance Misuse National Injectable Opioid Agonist Treatment Steering Committee has released a new guideline.
The authors suggest that removing X-waiver requirements would allow healthcare providers to better assist patients with opioid use disorder.
Federal health officials have proposed a revamp of patient confidentiality regulations to encourage coordination among medical professionals treating people for opioid addiction.
A fivefold increase was seen in Medicaid-covered prescriptions for buprenorphine during 2011 to 2018.
Individuals taking extended-release injection naltrexone for opioid use disorder may be less likely to drop out of treatment after a single use of opioids compared with patients receiving placebo.
Regional variation in naloxone dispensing considerable; rates lowest in most rural counties.
Prenatal opioid exposure may be associated with poorer cognitive and motor development in children from age 6 months to adolescence.
An estimated 20 million people in the United States meet the criteria for substance use disorder.